Your browser doesn't support javascript.
loading
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Rugo, Hope S; Delord, Jean-Pierre; Im, Seock-Ah; Ott, Patrick A; Piha-Paul, Sarina A; Bedard, Philippe L; Sachdev, Jasgit; Le Tourneau, Christophe; van Brummelen, Emilie M J; Varga, Andrea; Salgado, Roberto; Loi, Sherene; Saraf, Sanatan; Pietrangelo, Dina; Karantza, Vassiliki; Tan, Antoinette R.
Affiliation
  • Rugo HS; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Hope.Rugo@ucsf.edu.
  • Delord JP; Department of Medical Oncology, Institut Claudius Regaud, Oncolpole-Toulouse, France.
  • Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bedard PL; Division of Medical Oncology, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Sachdev J; Breast and GYN Early Trials Program, Scottsdale Healthcare Shea Medical Center, Scottsdale, Arizona.
  • Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud, France, INSERM U900 Research Unit, Saint-Cloud France, and Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France.
  • van Brummelen EMJ; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Varga A; Drug Development Department, Gustave Roussy, Villejuif, France.
  • Salgado R; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
  • Loi S; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
  • Saraf S; Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Pietrangelo D; Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Karantza V; Department of Clinical Oncology, Merck & Co., Inc., Kenilworth, New Jersey.
  • Tan AR; Division of Medical Oncology, Department of Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Clin Cancer Res ; 24(12): 2804-2811, 2018 06 15.
Article in En | MEDLINE | ID: mdl-29559561
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptors, Estrogen / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2018 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptors, Estrogen / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized / Antineoplastic Agents, Immunological Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2018 Document type: Article Country of publication: United States